Lupus Nephritis Diagnosis
Lupus Nephritis Diagnosis
Diagnosis in lupus nephritis has two layers. The first establishes that the kidney is involved at all, and it is made from urine and blood tests. The second establishes what the involvement actually is, and it is made from a kidney biopsy. The biopsy is the layer that people find hardest to accept, and it is also the layer that decides the treatment — which is why it is standard here rather than reserved for difficult cases.
Why the biopsy is the centre of the assessment
Blood and urine can tell you that the kidney is involved and how much it is leaking. They cannot tell you what the inflammation is made of, and in lupus nephritis that is the question the treatment is built on. Three things can only be obtained from tissue.
| Question | Why it changes what is done |
|---|---|
| Which class is this? | Some classes are managed by treating the lupus rather than the kidney. Others need induction immunosuppression. The class is the starting point of the plan |
| How much of it is active? | Active inflammation is what responds to treatment. Its extent tells you how hard to push, and it gives you a baseline to judge the response against |
| How much is already scar? | Scar does not respond, and heavy immunosuppression given for scar is risk without benefit. Its extent is what stops treatment from escalating when it should not |
The procedure itself is short. A needle is passed into the kidney under imaging guidance, usually taking two small cores of tissue, which are examined by light microscopy, immunofluorescence and electron microscopy. Because bleeding is the main risk, the biopsy is preceded by checks of blood pressure, clotting and blood counts, and by a review of anything that increases bleeding — including anti-inflammatory painkillers and blood thinners — so that these can be adjusted in advance. Most people are observed for several hours afterwards and go home the same day or the next.
One honest qualification, because it matters for decisions rather than for reassurance: a biopsy is not always possible. Serious bleeding risk, uncontrolled blood pressure, a single working kidney where the risk is judged unacceptable, or a person who declines it are all situations where treatment is started from the clinical picture instead. That is a considered fallback rather than an equivalent route, and it is documented as such.
How each class changes the treatment
The classification is descriptive rather than a ranking of how unwell someone is, but each pattern has a usual position on how much treatment it warrants. The table below is that correspondence, not a substitute for reading your own report with your own clinician.
| Class | Usual position on treatment | What to watch for |
|---|---|---|
| Class I | Treatment is directed at the lupus rather than at the kidney, with monitoring of the urine | Not a reason to stop monitoring: the class can change over time |
| Class II | Usually mild; kidney-directed immunosuppression is often not required | Blood pressure and protein still have to be managed, and activity elsewhere still treated |
| Class III | Induction treatment, with strength set by how much of the lesion is active | A combined class III plus V behaves differently from class III alone and should be treated as a proliferative lesion |
| Class IV | The most actively treated class: induction followed by a long maintenance period | Segmental and global patterns are both class IV; what varies is the proportion of active and chronic change |
| Class V | Driven by how much protein is being lost, and by whether a proliferative class is present alongside | A pure membranous pattern with modest protein may be watched; heavy protein loss or a combined class changes the decision |
| Class VI | Immunosuppression generally steps back, because most of the filtering units are already scarred | Care turns to protecting what remains and planning replacement — and to being explicit that the aim has changed |
Two further points belong with this table. First, a class can be reported with a combination — class III plus V, or IV plus V — and combinations take the treatment of the proliferative component, because it is the proliferative component that threatens the kidney. Second, a class can transform between biopsies, which is why a change in the clinical course is a reason to reconsider the tissue rather than to continue on an earlier report indefinitely.
Active or scarred — the distinction that decides how far to go
Two features are scored separately on every biopsy: an activity index, describing injury that is fresh, and a chronicity index, describing injury that has already turned to scar. The distinction is not academic. It is what tells a clinician whether to escalate, to hold, or to step back.
| Active change — responds to treatment | Chronic change — does not respond |
|---|---|
| Increase in cells within the filtering tuft | Filtering units already replaced by scar |
| Karyorrhexis and necrosis of the tuft | Crescents that have become fibrous rather than cellular |
| Cellular crescents | Scarring between the tubules, and wasting of the tubules themselves |
| Deposits beneath the lining of the capillaries | Thickening of the small vessel walls after long-standing damage |
The practical consequences run in both directions. Where activity dominates and chronicity is limited, escalation is worth it, because there is something to save and something to gain. Where chronicity dominates, more immunosuppression generally does not restore function and adds infection risk, so the aim shifts to protecting what remains, controlling blood pressure and protein, and planning ahead. And where both are present together, the balance is a matter of judgement — which is exactly the situation in which a second opinion has something to offer.
A partial response is not a failure. Treatment of lupus nephritis is judged over months, against targets agreed at the outset, and the shape of the response over time is read together with the biopsy findings rather than instead of them.
What the blood tests add, and what they cannot tell you
The blood tests are how the disease is tracked between biopsies. They are sensitive and they move early, but each has a limitation worth knowing, because it is the limitations that explain why a biopsy is still needed.
| Test | What it shows — and what it cannot |
|---|---|
| Complement C3 and C4 | Falls as immune activity consumes complement, often before symptoms. It reflects activity elsewhere in the body too, not only in the kidney |
| Anti-dsDNA antibodies | Rises with activity in many people and is a useful trend. Some people flare without a rise, and some have high levels without active kidney disease |
| Antinuclear antibody, anti-Smith | Supports the diagnosis of lupus. A positive result does not measure how active the disease is today |
| Antiphospholipid antibodies | Identifies an added risk of clotting, with implications for treatment and for pregnancy. Not a measure of kidney inflammation |
| Blood counts | Low white cells, low platelets and anaemia reflect lupus activity or the effect of treatment — and the two have to be told apart |
| Inflammatory markers | Useful mainly for their negative value: a sharply raised C-reactive protein suggests infection rather than a lupus flare, which changes the whole decision |
What no blood test provides is the pattern of injury inside the tissue. That is why complement, antibody and urine results are used to decide when to look, and the biopsy is used to decide what is there.
Monitoring after diagnosis, and when a repeat biopsy is considered
After the diagnosis, the work becomes rhythm rather than investigation. Checks are closer together while the disease is active, most often every one to three months, and spread out to every three to six months once the results have been stable for a sustained period. Each check combines urine, blood and a conversation about lupus activity elsewhere in the body.
| At each visit | The purpose |
|---|---|
| Urine sediment and protein measurement | Is inflammation active, and is protein falling towards the target agreed at the outset? |
| Creatinine and filtration rate | Is function stable across readings, or is it falling? |
| Complement and anti-dsDNA | Has immune activity changed in a way that predicts a flare? |
| Blood pressure | Is the most modifiable contributor to further damage controlled? |
| Blood counts and a medicine review | Are the medicines doing something they should not, and does the dose still match the disease? |
| The rest of the body | Is there a flare elsewhere — skin, joints, lungs, blood — that the kidney tends to follow? |
A repeat biopsy is considered rather than scheduled. The usual triggers are a disease that does not respond as expected, a new flare after a period of remission, or a change in the clinical picture suggesting the pattern has transformed. What a repeat biopsy would change decides whether it is done: if the answer would not alter the treatment, the procedure is not worth its risk.